X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
The company intends to use the net proceeds for clinical trials and product development of KVD900 (sebetralstat), which is a plasma kallikrein inhibitor designed to offer people living with hereditary Angioedema medications.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $160.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 15, 2024
Details:
The net proceeds will be used for the clinical development of KVD900 (sebetraslat), which is an oral plasma kallikrein inhibitor used for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2024
Details:
KVD900 (sebetralstat) is an investigational novel, oral plasma kallikrein inhibitor, which is being developed for the treatment of hereditary angioedema.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
KalVista is developing KVD900 (sebetralstat) as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. sebetralstat was well tolerated and led to rapid suppression of plasma kallikrein activity.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
KVD900 (sebetralstat) is a potent inhibitor of PKa with the potential for rapid suppression of HAE attacks. The Company intends to use the proceeds to fund clinical trials, commercial sales development, research, working capital and other general corporate purposes.
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $58.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 27, 2022
Details:
KVD900 (sebetralstat) is an oral plasma kallikrein inhibitor and the most advanced compound in our portfolio of candidates for the treatment of hereditary angioedema (HAE).
Lead Product(s): Sebetralstat
Therapeutic Area: Genetic Disease Product Name: KVD900
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
